Hypera S.A. / Takeda Pharmaceutical Company Limited
2020 · Asset Purchase · $825M · Complete
Announcement Sentiment
100
Strongly positive
Takeda agreed to divest a portfolio of select OTC and prescription products in Latin America (Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, Peru) to Brazilian pharma Hypera for $825M, part of Takeda's $10B non-core asset divestiture plan post-Shire acquisition. Transaction closed in 2021.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedMar 02, 2020
ClosedJan 29, 2021
Deal value$825M
Deal typeAsset Purchase
Therapeutic areaMultiple (OTC and prescription)
IndicationsMultiple (OTC and prescription)
Key assetsPortfolio of OTC and prescription products in Latin America